More than half of early childhood hepatitis B virus exposures originate from non-maternal household contacts rather than birth mothers, according to a Kaiser Permanente study presented at IDWeek 2026. The findings arrive as federal agencies roll back universal birth vaccination policies, warning that chronic pediatric infections could surge.
When the U.S. Centers for Disease Control and Prevention changed its decades-old immunization guidance in late 2025, public health policy moved away from giving every newborn a hepatitis B shot within 24 hours of birth. The updated framework restricts the neonatal dose to infants born to mothers with active infections or unknown status.
A retrospective cohort study analyzed medical records for more than 158,000 children younger than 5 across Northern California to examine non-maternal infection risks. Investigators identified 2,024 children sharing a residence with someone carrying an active hepatitis B infection. Among those exposed youngsters, 58.2% encountered the virus through a household member who was not their birth mother.
Study Reveals Non-Maternal Exposure Risks
The study found that these non-maternal household contacts were predominantly male, with a median age of 44, compared to a median age of 38 for birth mothers. Because hepatitis B transmits easily through shared bodily fluids like blood, saliva, and tears—and can remain viable on ambient household surfaces for up to a week—infants living with chronic carriers face continuous everyday exposure risks long before childcare or school entry immunization mandates take effect.
No one knows the status of everyone a child may come into contact with, and vaccinating infants at birth protects against known and unknown potential sources of transmission. The hepatitis B vaccine is a safe and effective way to protect against HBV infection.
Karen B. Jacobson, MD, MPH
Immunization uptake rates also reflected disparities based on exposure source. While 100% of infants born to infected mothers received their hepatitis B vaccination within seven days of birth, coverage dropped to 93.5% for children exposed to other household members and fell to 86.7% for unexposed children.
Simulations Project Surging Pediatric Infections
To project what those policy changes mean for a generation of children, researchers at Mass General Brigham used a computer model to follow 3.6 million hypothetical babies born in the United States in 2026 through their first 20 years of life. Published in the Annals of Internal Medicine, the simulation compared universal birth dosing against two alternative scenarios: delaying the first dose until 2 months of age, and adopting a shared clinical decision-making approach.
The computer simulation estimated that delaying vaccination to 2 months would increase chronic hepatitis B infections by 19% over the universal birth-dose strategy. Under a shared decision-making framework—assuming vaccine uptake drops to 50% or 26% depending on model parameters—chronic pediatric infections would jump by 83% or more.
| Vaccination Strategy | Chronic Infections at Age 20 | HBV-Susceptible People at Age 20 |
|---|---|---|
| Universal Birth-Dose | 255 cases | 232,000 people |
| Delayed Dose (2 Months) | 303 cases | 474,000 people |
| Shared Decision-Making | 467 cases | 1.8 million people |
Regulators and Medical Societies Clash Over Policy
The Advisory Committee on Immunization Practices voted 8 to 3 to recommend individual-based decision-making for infants born to women who test negative for the virus. U.S. Health and Human Services Secretary Robert F. Kennedy Jr. defended the regulatory changes on social media, criticizing modeling simulations as theoretical projections rather than empirical outcome studies.
Pediatric infections in the United States had plummeted from more than 25,000 cases annually in 1985 down to fewer than 100 reported cases by 2024 following decades of universal birth-dose protection.
Even a small increase in childhood HBV infections could have large clinical, public health, and economic effects.
Amir Mohareb, MD, infectious disease physician at the Center for Global Health at Mass General Brigham